Turn on your bedroom humidifier 30 minutes before sleep
Glules vgtales
B12 injections may help with mood and energy, but they work best when paired with consistent sleep and mindful stress management

What's New: August 2026 Update TRIUMPH-2 CONFIRMED (July 23, 2026): Obesity + type 2 diabetes trial, 1,152 patients up to 20.8% weight loss (12mg) and up to -1.6 percentage points HbA1c reduction at 80 weeks TRIUMPH-3 CONFIRMED (July 23, 2026): Obesity + established cardiovascular disease trial, 1,949 patients up to 22.6% weight loss (12mg) at 80 weeks, plus significant improvements in triglycerides, blood pressure, and inflammatory markers All four core TRIUMPH registrational trials are now complete TRIUMPH-4, TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 have all reported positive topline results TRIUMPH-1 reminder: 45.3% of patients on 12mg lost 30% of body weight, and a 104-week extension in patients with BMI 35 reached up to 30.3% average weight loss surgical-level outcomes that remain the strongest efficacy data in the program Filing type confirmed: BLA, not NDA Eli Lilly will submit a Biologics License Application (retatrutide is regulated as a biologic), now expected Q1 2027 (shifted from the previously estimated Q4 2026) Lilly's own statement: "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea" TRIUMPH-Outcomes (cardiovascular and kidney outcomes, ~10,000 patients) remains separate and ongoing not expected until 20282029, and not required for initial approval Current Status: Where Things Stand Retatrutide is an investigational medication developed by Eli Lilly

Tell the JourneyLite team if you are pregnant, breastfeeding, or planning pregnancy
Achieving a healthy body fat percentage